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A B S T R A C T
Purpose
Lung cancer is the leading cause of cancer-related mortality among women. The role of hormone
replacement therapy (HRT) in lung cancer development is unclear.
Patients and Methods
We evaluated a prospective cohort of 36,588 peri- and postmenopausal women aged 50 to 76
years from Washington State recruited in 2000 to 2002 (Vitamins and Lifestyle [VITAL] Study).
Lung cancer cases (n  344) were identified through the Seattle-Puget Sound Surveillance,
Epidemiology, and End Results cancer registry during 6 years of follow-up. Hazard ratios (HRs)
associated with use and duration of specific HRT formulations were calculated for total incident
lung cancer, specific morphologies, and cancer by stage at diagnosis.
Results
After adjusting for smoking, age, and other potential confounders, there was an increased risk of
incident lung cancer associated with increasing duration of estrogen plus progestin (EP) use (HR 
1.27 for EP use 1 to 9 years, 95% CI, 0.91 to 1.78; and HR  1.48 for EP use  10 years, 95%
CI, 1.03 to 2.12; P for trend  .03). There was no association with duration of unopposed estrogen use.
Duration of EP use was associated with an advanced stage at diagnosis (P for trend  .03).
Conclusion
Use of EP increased the risk of incident lung cancer in a duration-dependent manner, with an
approximate 50% increased risk for use of 10 years or longer. These findings may be helpful for
informing women of their risk of developing lung cancer and delineating important pathways
involved in hormone metabolism and lung cancer.
J Clin Oncol 28:1540-1546. © 2010 by American Society of Clinical Oncology
INTRODUCTION
Lung cancer is the leading cause of cancer mortality
for women in the United States.1 Tobacco causes
90% of lung cancers,2 and cessation is the only rec-
ommended method for prevention.3 However, the
prevalence of tobacco use remains high,4 and lung
cancer risk persists after smoking cessation.5 Ac-
cordingly, it is important to evaluate additional mo-
dalities that affect the risk of incident lung cancer.
Exogenous hormones may impact lung cancer
development. The biologic mechanisms underlying
hormone metabolism and lung cancer are not clear
in direction or magnitude.6,7 Studies evaluating hor-
mone replacement therapy (HRT) use and incident
lung cancer have had conflicting results and many
have had limitations such as not examining indi-
vidual HRT formulations, duration of use, lim-
ited adjustment for the confounding effects of
tobacco use, and/or limited to nonsmokers.8-21
There is concern that associations found in observa-
tional studies may not be replicated in placebo-
controlled trials as shown in trials of both lung
cancer chemoprevention and HRT,22-24 and several
trials have suggested that estrogen plus progestin
may be associated with an increased risk of lung
cancer incidence25 and death.26-28
Given these conflicting findings, studies of HRT
and lung cancer should examine the effects of dura-
tion and HRT formulation in the association be-
tween HRT and lung cancer and adjust for the
confounding of smoking to decrease the chances of
misconstruingtherelationshipbetweenHRTandlung
cancer.29 We used the prospective cohort study (Vi-
tamins and Lifestyle [VITAL] study) to evaluate the
association of HRT use with incident lung cancer.
PATIENTS AND METHODS
Subjects
The methods used in the VITAL cohort study have
been described.30 From October 2000 to December 2002,
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we mailed questionnaires to 168,953 women aged 50 to 76 years who lived in
the area covered by the Seattle-Puget Sound Surveillance, Epidemiology, and
End Results (SEER) registry, using names from a commercial mailing com-
pany. A total of 41,157 women (24.4%) returned the questionnaire, and of
those, 820 failed eligibility or quality control checks, leaving 40,337 women.
Baseline data included items on medication use, diet, medical history, personal
characteristics, and cancer risk factors. The responders were more educated
than the general population and smoked less currently, but were similar in
body mass index (BMI).30 The Fred Hutchinson Cancer Research Center’s
institutional review board approved the protocol.
The censored date was the date of withdrawal from the study, death,
move out of the SEER catchment area, or last date of linkage to SEER for
diagnosis of lung cancer. Deaths were ascertained by linkage to Washington
State death files, and moves out of the area from the National Change of
Address System, letters, and telephone calls.
For this report, we excluded participants with a previous diagnosis of
lung cancer (n  176) or for whom this datum was missing (n  86). We
excluded subjects whose lung cancer was identified on a death certificate only
or whose lung cancer morphology was lymphoma (n  4). We then excluded
subjects who were not perimenopausal or postmenopausal (n1,995). Lastly,
we excluded subjects with completely missing information regarding HRT use
(n  1,488), leaving 36,588 women.
Outcome Assessment: Lung Cancer
Participants were observed for lung cancer occurring from baseline
through December 31, 2007, through linkage to SEER. SEER has accurate
and complete data collection31 and is reliable for lung cancer histology.32 If
a subject had multiple diagnoses of lung cancer, we used the time to
first diagnosis.
Exposure Assessment: HRT Use
Hormone replacement therapy use was ascertained by inquiring about
use of prescription estrogen and progestin as pills or patches, excluding oral
contraceptives. Information was obtained on hormone therapy use status
(never, former, current) and years of use (categorized as  1, 1 to 4, 5 to 9, 10
to 14, or  15). Past HRT use for less than 1 year was combined with no use
(never). Current HRT use less than 1 year was classified as 1 to 4 years of use.
Years of estrogen plus progestin (EP) use and years of estrogen-only use were
computed separately. The reference group was users of neither type of HRT.
Women with periods of exposure to both unopposed estrogen and EP had
the relevant years of use included in both analyses. Subjects with estrogen only
use were excluded from the duration of EP use analysis and users of EP
only were excluded from the duration of estrogen use analysis.
Covariates
Tobacco. Smokers were defined as individuals who smoked at least one
cigarette per day for at least a year. Smoking status was classified as never,
current, quit 10 years or more, or quit less than 10 years ago, as of the date of
questionnaire completion. Duration of smoking was estimated by the number
of years smoked, intensity was estimated by the usual number of cigarettes
smoked per day, and pack-years was computed as years smoked  cigarettes
per day/20.
Gynecologic factors. Perimenopausal women were defined as having
menses in the past year that were not regular. Women were assumed to be
postmenopausal if they had no periods in the year before baseline, had ever
used hormone therapy, had had a bilateral oophorectomy, or were  60 years
at baseline. Age at menopause was categorized in 5-year increments ( 39 to
 55 years) to the age at which menstrual periods ended or age of first use of
hormone therapy or were 60 years old at baseline, whichever came first.
Women who reported a hysterectomy without bilateral oophorectomy were
considered to be postmenopausal if they had ever used hormone therapy or
were  55 years at baseline. For those women, age at menopause was set to the
age at which they first used hormone therapy (if before age 55 years); other-
wise, it was set to missing.
Additional covariates. Subjects reported age, race/ethnicity, marital sta-
tus, and education. Previous history of cancer and self-report of diagnosed
chronic obstructive pulmonary disease (COPD) were recorded. We catego-
rized family history as none or at least one first-degree relative with lung
cancer. BMI was calculated from the respondent’s self-reported current weight
and height, measured as kilograms per square meters.
Daily servings of fruit were assessed by a food frequency questionnaire
that was an adaptation from the Women’s Health Initiative and other
studies,33-35 with the addition of highly supplemented foods. Subjects were
extensively queried about use of nonsteroidal anti-inflammatory drugs and
supplemental vitamins.
Statistical Analysis
All analyses were performed using STATA SE-9 (StataCorp, College
Station, TX). For the main analysis, Cox regression using robust SEs36 was
used to estimate the hazard ratios (HRs) for associations of HRT use categories
and lung cancer risk. Age was the time variable with left truncation for age at
baseline and censoring (right truncation) as described above. Subjects with
missing data on HRT use or other covariates in the model were excluded from
analysis. We analyzed four exposure variables: HRT use, analyzed by categories
of use (never, former, and current); ever-use of specific formulations of HRT
(none, estrogen only, EP only, and both); duration of use of EP; and
duration of estrogen only. We treated each duration of use category as a
continuous trend variable to assess for trends in lung cancer risk, comparing
each category with no use.
On the basis previous work, we used a model that adjusts for confound-
ing by cigarette smoking that included years smoked, pack-years, and a
squared pack-years term.37 We decided a priori to include age, nonwhite
race/ethnicity, history of cancer, family history of lung cancer, COPD, BMI
(categoric, including missing as a category), age at menopause (categoric,
including missing as a category), and hysterectomy/oophorectomy status. We
evaluated whether other factors associated with lung cancer risk (nonsteroidal
anti-inflammatory drug use, supplemental vitamin E, education, and daily
servings of fruit) individually confounded the association of HRT use with
lung cancer in the adjusted model. None changed the point estimates of the
HRT variables by more than 10% or the 5% level of significance so were
not included.
We examined whether the associations of HRT with incident lung
cancer use differed by morphology by treating each morphology as a
separate outcome, exclusive of the other morphologies, compared with sub-
jects who did not develop lung cancer. We also looked for differences of the
HRT–lung cancer associations by smoking status and BMI subgroups. Be-
cause few never smokers developed lung cancer, we did not include this group
in the stratified smoking status analyses. Likelihood ratio tests were conducted
to assess the interaction between HRT use, analyzed as trend variables, and the
subgroups. P values for interaction were obtained to compare the fit of the
models with the interaction terms and without them. Finally, we examined
whether the associations of HRT with incident lung cancer use differed by local
versus regional/advanced/unknown stage at diagnosis by treating these stages
as separate outcomes, exclusive of the other stages, compared with subjects
who did not develop lung cancer. Unknown stage was combined with the latter
groups because staging information is often missing in advanced cases that are
not candidates for surgery. P values less than .05 were considered statisti-
cally significant.
RESULTS
A total of 36,588 subjects met inclusion criteria and were observed for
a mean of 5.9 years (standard deviation  1.2 years). Three hundred
forty-four patients developed lung cancer. Non–small-cell lung cancer
(NSCLC) accounted for 77.0% of the total: adenocarcinoma (n  141
[41.0%]), squamous cell (n  47 [13.7%]), large cell (n  9 [2.6%])
and NSCLC, not otherwise specified (n68 [19.8%]). Small-cell lung
cancer (SCLC) accounted for 12.5% of the total lung cancers. Other
lung cancers, mostly comprising carcinomas not otherwise specified
and carcinoid/neuroendocrine tumors, accounted for 10.5% of the
total. Seventy-three subjects (21.2%) were diagnosed with a local stage
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at diagnosis, 97 (28.2%) regional, 164 (47.7%) distant, and 10 (2.9%)
had an unknown stage.
When stratified by the formulation of HRT used, the subjects
were similar in most respects (Table 1). The EP only users were
somewhat younger with fewer pack-years and years of smoking. This
group also had a smaller percentage with a history of cancer but a
higher percentage without a hysterectomy.
After adjustment, current and former use of HRT was associated
with a nonsignificantly elevated risk of incident lung cancer
(HR  1.23, 95% CI, 0.92 to 1.66; and HR  1.18, 95% CI, 0.86 to
1.63, respectively; Table 2). Compared with no use of HRT, use of the
estrogen plus progestin formulation only was associated with an in-
creased risk of incident lung cancer (HR  1.47; 95% CI, 1.06 to 2.04).
Use of unopposed estrogen only and use of both formulations were
not associated with lung cancer.
There was evidence of a dose response associated with the dura-
tion of EP use. Use of EP for  10 years was associated with an
increased risk of lung cancer compared with no use of HRT
(HR  1.48; 95% CI, 1.03 to 2.12; P for trend  .03). Conversely, there
was no association between duration of estrogen use and lung cancer.
Table 1. Characteristics of Cohort Stratified by Formulation of Hormone Replacement Therapy Use
Characteristic
Overall Cohort
(N  36,588) No HRT Use E Use Only EP Use Only Use of Both
No. % No. % No. % No. % No. %
Age, years
Mean 62.4 62.8 63.1 59.5 65.0
SD 7.3 7.9 7.3 6.0 6.3
Smoking status
Never smoker 20,141 55.4 6,750 57.5 5,894 54.0 4,969 56.1 2,149 51.5
Quit  10 years 11,150 30.7 3,298 28.1 3,393 31.1 2,803 31.6 1,477 35.4
Quit  10 years 2,166 6.0 614 5.2 739 6.8 501 5.7 273 6.6
Current smoker 2,899 8.0 1,084 9.2 899 8.2 592 6.7 271 6.5
Pack-years
Mean 22.9 23.7 23.7 20.0 23.5
SD 21.6 21.9 22.2 19.7 21.9
Years smoked
Mean 22.7 23.6 23.7 19.9 23.3
SD 13.9 14.4 13.8 13.0 13.7
Race/ethnicity
White 33,395 93.3 10,539 91.4 10,054 93.6 8,291 94.3 3,935 95.6
Socioeconomic variables
Married 23,973 67.1 7,143 62.1 7,319 68.4 6,245 71.4 2,856 69.4
College graduate or higher 12,134 33.9 3,927 34.1 2,765 25.8 3,969 45.2 1,348 32.8
Medical history
Cancer 5,981 16.4 2,310 19.5 1,879 17.1 1,029 11.6 647 15.4
COPD 1,450 4.0 428 3.6 559 5.1 232 2.6 192 4.6
Family history of lung cancer† 4,730 13.1 1,451 12.5 1,593 14.7 1,030 11.7 570 13.7
BMI, kg/m2
Underweight ( 18.5) 495 1.5 177 1.6 135 1.3 114 1.3 55 1.4
Normal (18.5-24.9) 13,556 39.7 4,052 37.4 3,830 37.2 3745 44.2 1,726 43.5
Overweight (25-29.9) 11,484 33.6 3,544 32.7 3,574 34.7 2,796 33.0 1,378 34.8
Obese ( 30) 8,623 25.2 3,068 28.3 2,762 26.8 1,822 21.5 806 20.3
Gynecologic factors
Hysterectomy status
None 21,714 59.4 9,493 80.3 1,238 11.3 8,219 92.3 2,552 60.8
Hysterectomy 8,208 22.4 1,565 13.2 5,434 49.4 271 3.0 682 16.2
Oophorectomy 201 0.6 67 0.6 56 0.5 48 0.5 25 0.6
Hysterectomy/oophorectomy 6,465 17.7 702 5.9 4,267 38.8 366 4.1 942 22.4
Age at menopause, years
 39 3,640 10.9 487 5.2 2,239 21.4 193 2.2 607 14.6
40-44 4,934 14.8 896 9.5 2,364 22.6 718 8.2 868 20.9
45-49 9,862 29.6 2,401 25.5 3,093 29.6 2,824 32.4 1,366 32.9
50-54 12,870 38.6 4,582 48.7 2,556 24.4 4,362 50.0 1,172 28.2
 55 2,052 6.2 1,042 11.1 210 2.0 629 7.2 143 3.4
NOTE. Percentages are of nonmissing data and are for the overall cohort and for each formulation of HRT use category. Numbers may not sum to 100% secondary
to rounding and missing data. Less than 5% of the overall cohort had missing data except for the following with percentages listed for each category of BMI (7.1%)
and age at menopause (9.7%). A total of 1.8% of the overall cohort was missing information on the formulation of HRT used and not included in this summary table.
Abbreviations: HRT, hormone replacement therapy; E, unopposed estrogen; EP, estrogen plus progestin; SD, standard deviation; COPD, chronic obstructive
pulmonary disease; BMI, body mass index.
Among current or former smokers.
†First-degree relative with lung cancer.
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When we stratified the analysis by NSCLC and SCLC, no status,
formulation, or duration of HRT use was statistically significantly
associated with either morphology, though all except estrogen use
for  10 years were associated with increased risks (Table 3). No
category of HRT use, formulation, or duration was significantly asso-
ciated with adenocarcinoma when this morphology was analyzed
separately (data not shown).
There was no clear evidence of effect modification by either
smoking status or BMI. No category of HRT use, formulation, or
duration was significantly associated with incident lung cancer when
stratified by smoking status or BMI categories (data not shown).
No HRT use, formulation, or duration category was significantly
associated with local stage at diagnosis (Table 4). However, EP use
(HR  1.52; 95% CI, 1.06 to 2.19; P  .04) was associated with more
advanced stages, and increasing duration of EP use was associated as
well (P for trend  .03). Unopposed estrogen use and duration were
not associated with advanced stages at diagnosis.
DISCUSSION
The use of EP was associated with an increased risk of incident lung
cancer in this study. Although HRT use has declined38 and is not
recommended except for short-term treatment of menopausal symp-
toms,39 our results indicate millions of women may remain at risk of
developing lung cancer. We found that the association of HRT with
lung cancer was duration dependent, with the highest risk for users of
EP  10 years. Use of EP was also associated with an advanced
stage at diagnosis in a duration-dependent manner. We do not have
the power to estimate a safe length of HRT use.
There were not large differences in the associations between
NSCLC and SCLC. Similarly, smoking status did not seem to modify
the associations. A recent cohort study that also showed increased
risks of lung cancer associated with HRT use did not see differences
in the association with regard to histology and smoking status.11
Although obesity may modify the association between HRT and lung
cancer,21 BMI was not an effect modifier in our study. The relatively
small number of cases in each subcategory limits our ability to de-
tect differences.
Previous studies of the association between HRT and lung cancer
have been mixed.8-21 In the Cancer Prevention Study II, current use of
any HRT was associated with a decreased risk of lung cancer (relative
risk0.76; 95% CI, 0.62 to 0.92) that was not duration dependent and
did not differ by formulation.9 A case-control study found a duration-
dependent decreased risk for lung cancer with HRT use (odds ra-
tio  0.88; 95% CI, 0.78 to 1.00 for each duration quartile) and did not
differ by formulation.20 Another case-control study reported protec-
tive associations with HRT use that did not differ between unopposed
estrogen and EP.18 Women in the Canadian National Breast Screen-
ing Study using HRT (formulation not specified) for 10 years or
longer, however, had an elevated risk (HR  1.51; 95% CI, 1.14 to
Table 2. Hazard Ratios for the Association of Hormone Replacement Therapy Use With Incident Lung Cancer
HRT Variable
Noncases
(n  36,244) Cases (n  344)
Age-Adjusted HR 95% CI Adjusted HR 95% CINo. % No. %
HRT status
Never user 11,642 33.5 104 31.1 Ref Ref
Former user 5,668 16.3 73 21.9 1.24 0.92 to 1.68 1.18 0.86 to 1.63
Current user 17,451 50.2 157 47.0 1.13 0.88 to 1.45 1.23 0.92 to 1.66
HRT formulation
No use 11,723 32.9 104 31.1 Ref Ref
E use only 10,878 30.6 117 35.0 1.19 0.92 to 1.57 1.04 0.73 to 1.48
EP use only 8,840 24.8 64 19.2 1.13 0.82 to 1.10 1.47 1.06 to 2.04
Use of both 4,152 11.7 49 14.7 1.16 0.82 to 1.86 1.24 0.86 to 1.79
Duration
EP†
No HRT use 11,723 47.4 104 47.9 Ref Ref
1-9 years 8,688 35.2 59 27.2 1.03 0.75 to 1.42 1.27 0.91 to 1.78
 10 years 4,304 17.4 54 24.9 1.29 0.92 to 1.81 1.48 1.03 to 2.12
P for trend‡ .17 .03
E use§
No HRT use 11,723 51.9 104 47.1 Ref Ref
1-9 years 3,972 17.6 37 16.7 1.31 0.89 to 1.91 1.14 0.73 to 1.78
 10 years 6,906 30.6 80 36.2 1.15 0.86 to 1.54 0.87 0.56 to 1.34
P for trend .31 .53
NOTE. Percentages are of nonmissing data. All HRT variables had less than 2% missing data. Numbers may not sum to 100% secondary to rounding and
missing data.
Abbreviations: HRT, hormone replacement therapy; HR, hazard ratio; Ref, reference; E, unopposed estrogen; EP, estrogen plus progestin.
Adjusted for age, pack-years, pack-years squared, years smoked, personal history of cancer, family history of lung cancer, chronic obstructive pulmonary disease,
body mass index (categorical, including missing as a category), age at menopause (categorical, including missing as a category), hysterectomy type, and nonwhite
race/ethnicity.
†Years of EP use alone. Reference group is subjects who never used any form of HRT. Users of E only are excluded from the analysis.
‡P for trend analyses by continuous categories.
§Years of E use alone. Reference group is subjects who never used any form of HRT. Users of EP only are excluded from the analysis.
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1.99).11 The Heart and Estrogen/Progestin Replacement Study
(HERS) found a nonsignificantly increased risk of lung cancer for
women randomly assigned to conjugated EP (HR  1.39; 95% CI,
0.84 to 2.28).25
Recent Women’s Health Initiative analyses found that subjects
randomly assigned to EP had more lung cancer deaths than those
taking placebo.26,27 A retrospective study also found decreased sur-
vival among HRT users with lung cancer.28 SEER collects mortality
data, but we did not analyze lung cancer mortality because we do not
have information on HRT use after diagnosis. However, to explore a
possible explanation for the effect of HRT on lung cancer mortality,
we analyzed the association of HRT use with stage at diagnosis and
found an increased risk of advanced stages at diagnosis with EP,
consistent with the Women’s Health Initiative results on lung cancer
mortality.26,27 Although the mechanisms underlying this association
are unknown, EP may lead to more aggressive disease, may mask
early symptoms, and/or users may be less likely to seek or receive
medical care in a timely fashion.
The mechanisms that contribute to the association between ex-
ogenous hormone therapy and lung cancer risk are complex, with
likely genetic and environment interactions.6,40 Estrogen and pro-
gesterone receptors are found in NSCLC tumors41,42 and the quan-
tity of estrogen receptors is associated with decreased recurrence-free
survival.42 Estradiol promotes growth in NSCLC cell lines that is
blocked by antiestrogens.43 Similarly, a mouse model showed that
estradiol increased the proliferative index of cells that had been initi-
ated by expression of oncogenic Kras and concurrent deletion of
Tp53.44 A combination of an estrogen antagonist and epidermal
growth factor receptor tyrosine kinase inhibitor decreased tumor vol-
ume more than either drug alone in vivo in xenograft models41,45 and
in vitro.46 Evidence for a protective association of HRT has been
shown. Low levels of insulin-like growth factor 1 are associated with
reduced risk of lung cancer,47 and HRT has been shown to decrease
insulin-like growth factor 1 levels.14 Finally, a recent study found
several associations between single nucleotide polymorphisms in
genes involved with estrogen metabolic pathways and an increased
risk of lung cancer.48
Our study has several strengths. We used a large, prospective,
population-based cohort study design. We were able to analyze the
duration of HRT use in a dose-response manner over a long period of
time that is likely necessary for biologic plausibility. We controlled for
the strong confounding effect of tobacco and examined multiple other
variables that affect the risk of incident lung cancer. Finally, the SEER
database is complete and accurate, so there is minimal risk of out-
come misclassification.
Table 3. Hazard Ratios for the Association of Hormone Replacement
Therapy Use With Incident Lung Cancer Stratified by Morphology
HRT Variable
NSCLC (n  265) SCLC (n  43)
HR 95% CI HR 95% CI
HRT status
Never user Ref Ref
Former user 1.07 0.74 to 1.56 1.48 0.60 to 3.69
Current user 1.16 0.82 to 1.63 2.15 0.95 to 4.87
HRT formulation
No use Ref Ref
E use only 1.03 0.68 to 1.55 2.10 0.85 to 5.16
EP use only 1.22 0.83 to 1.79 1.65 0.58 to 4.70
Use of both 1.25 0.83 to 1.89 1.96 0.68 to 5.61
Duration
EP use†
No HRT use Ref Ref
1-9 years 1.23 0.84 to 1.80 1.36 0.45 to 4.07
 10 years 1.27 0.83 to 1.94 2.36 0.72 to 7.71
P for Trend‡ 0.22 0.17
E use§
No HRT use Ref Ref
1-9 years 1.06 0.63 to 1.79 2.41 0.81 to 7.16
 10 years 0.91 0.54 to 1.53 1.83 0.68 to 4.94
P for trend‡ 0.73 0.22
Abbreviations: NSCLC, non–small-cell lung cancer; SCLC, small-cell lung
cancer; HRT, hormone replacement therapy; Ref, reference; HR, hazard ratio;
E, unopposed estrogen; EP, estrogen plus progestin.
Adjusted for age, pack-years, pack-years squared, years smoked, personal
history of cancer, family history of lung cancer, chronic obstructive pulmonary
disease, body mass index (categorical, including missing as a category), age at
menopause (categorical, including missing as a category), hysterectomy type,
and nonwhite race/ethnicity.
†Years of EP use alone. Reference group is subjects who never used any
form of HRT. Users of E only are excluded from the analysis.
‡P for trend analyses by continuous categories.
§Years of E use alone. Reference group is subjects who never used any form
of HRT. Users of EP only are excluded from the analysis.
Table 4. Hazard Ratios for the Association of Hormone Replacement






HR 95% CI† HR 95% CI†
HRT status
Never user Ref Ref
Former user 1.05 0.49 to 2.26 1.22 0.85 to 1.74
Current user 1.01 0.50 to 2.06 1.29 0.93 to 1.79
HRT formulation
No use Ref Ref
E use only 0.70 0.29 to 1.66 1.15 0.78 to 1.69
EP use only 1.27 0.60 to 2.69 1.52 1.06 to 2.19
Use of both 1.24 0.54 to 2.86 1.22 0.81 to 1.84
Duration
EP use‡
No HRT use Ref Ref
1-9 years 1.13 0.53 to 2.44 1.31 0.90 to 1.90
 10 years 1.29 0.57 to 2.91 1.52 1.02 to 2.28
P for trend§ .54 .03
E use
No HRT use Ref Ref
1-9 years 0.61 0.20 to 1.89 1.31 0.81 to 2.11
 10 years 0.53 0.18 to 1.55 0.97 0.61 to 1.54
P for Trend§ .26 .93
Abbreviations: HRT, hormone replacement therapy; HR, hazard ratio; Ref,
reference; E, unopposed estrogen; EP, estrogen plus progestin.
Regional, advanced, or unknown stage.
†Adjusted for age, pack-years, pack-years squared, years smoked, personal
history of cancer, family history of lung cancer, chronic obstructive pulmonary
disease, body mass index (categorical, including missing as a category), age at
menopause (categorical, including missing as a category), hysterectomy type,
and nonwhite race/ethnicity.
‡Years of EP use alone. Reference group is subjects who never used any
form of HRT. Users of E only are excluded from the analysis.
§P for trend analyses by continuous categories.
Years of E use alone. Reference group is subjects who never used any form
of HRT. Users of EP only are excluded from the analysis.
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Our results are similar to those observed in the randomized,
placebo-controlled HERS trial,25 but there are potential limitations of
our study. First, residual confounding may be a factor. We could not
adjust for environmental tobacco or occupational exposures that in-
crease lung cancer risk. However, we did adjust for several smoking
variables and did not find evidence of confounding by indication
from processes such as oophorectomy for which HRT is com-
monly taken. Second, the measurement of long-term use of HRT is
based on subject recall and was not measured repeatedly. The VITAL
questionnaire was validated for long-term use of supplements,49 sug-
gesting our measure of HRT is reasonably accurate. We expect that
exposure misclassification would have attenuated our results in this
prospective study. Generalizability may be limited because only 24%
of respondents returned the initial survey, but it is unlikely that selec-
tion bias could have affected our results because in a prospective
design, women cannot participate jointly based on exposure and fu-
ture (unknown) disease status.
Lung cancer is the second most common malignancy among
women and causes more deaths than breast cancer.1 Our results indi-
cate that the use of EP is associated with an increased risk of incident
lung cancer and advanced stages at diagnosis in a duration-response
manner. These findings represent an important contribution to cur-
rent evidence against HRT use, which may be useful for counseling
women about their risk of developing lung cancer, as well as
prompting further study about the biologic mechanisms underly-
ing this association.
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